Spinal cord stimulation
Ask the expert
The report presents a summary of the reimbursement situation for use of spinal cord stimulation. Indications include neuropathic and ischemic pain.
Clinical scenarios include trial insertion of electrodes and external stimulator, permanent implantation of spinal cord stimulator, adjustment/programming of stimulator, removal of stimulator, and replacement of battery of pulse generation.
The only reimbursement within public / statutory health insurance systems is considered.
The report includes essential information about reimbursement, including:
- Brief country-specific overview of reimbursement system
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions on indications or scenarios for the use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
- The Netherlands
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of the spinal cord stimulation devices include:
- Boston Scientific (Precision)
- Nevro (Senza)
- Stimwave (Freedom SCS)
- Abbot Vascular (BurstDR: Proclaim, Prodigy MRI IPG, St. Jude Medical Invisible Trial System; Eon)
- Medtronic (Intellis; SureScan: RestoreSenso, RestoreUltra, RestoreAdvanced, PrimeAdvanced)
- Saluda Medical (Evoke SCS System)
- Nuvectra (Algovita SCS)
- Med-Ally (VersaStim IPG Platform)
Table of content is not available at this moment.
In late March 2021, multiple new procedure codes were introduced by the Code Service of the Finnish National Health and Wellbeing Institution (THL), including ten neuromodulation codes, 54 codes in the ophthalmology area, and three codes in the cardiovascular area.Read more
On January 29, 2021, the Institute for the Hospital Remuneration System (InEK) has published the List of the requests for innovation funding (NUB) that were submitted by the hospitals in 2020. The medical technologies belonging to the cardiovascular, ENT, eHealth, gastrointestinal, neuromodulation, neurovascular, orthopedic, and other technology groups obtained positive status 1.Read more
On January 18, 2021, a new version of the List of Reimbursable Products and Services (LPPR) was published. It contains new devices included in the LPPR list in November-December 2020, as well as other modifications made during this period. Newly-introduced devices belong to the cardiovascular (coronary stents), orthopedic, neuromodulation (deep brain stimulation), peripheral vascular (stent-grafts to treat aortic abdominal aneurysm), and other areas of care.Read more
In December 2020, the National Institute for Health and Care Excellence (NICE) published one new medical technologies guidance (Zio XT for detecting cardiac arrhythmias), three Medtech innovation briefings (ReStore Soft Exo-Suit for gait rehabilitation, Cytosponge for detecting abnormal cells in the esophagus, and Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischemic pain). Also, nine clinical guidance documents were updated.Read more
In 2013, Norway established a framework “New Method” for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. In this framework, all innovations should undergo HTA before being funded. In the second half of 2020, eight new mini-HTA projects of medical technologies were launched in Norway: tissue allotransplantation, pain treatment via neuromodulation, among others.Read more